Home > Publications Database > TREM2 modulates differential deposition of modified and non-modified Aβ species in extracellular plaques and intraneuronal deposits. > print

001     162686
005     20240302115203.0
024 7 _ |a 10.1186/s40478-021-01263-x
|2 doi
024 7 _ |a pmid:34663480
|2 pmid
024 7 _ |a pmc:PMC8522217
|2 pmc
024 7 _ |a altmetric:115437449
|2 altmetric
037 _ _ |a DZNE-2021-01343
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Joshi, Pranav
|0 0000-0002-1153-0440
|b 0
245 _ _ |a TREM2 modulates differential deposition of modified and non-modified Aβ species in extracellular plaques and intraneuronal deposits.
260 _ _ |a London
|c 2021
|b Biomed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709305323_5355
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY
520 _ _ |a Progressive accumulation of Amyloid-β (Aβ) deposits in the brain is a characteristic neuropathological hallmark of Alzheimer's disease (AD). During disease progression, extracellular Aβ plaques undergo specific changes in their composition by the sequential deposition of different modified Aβ species. Microglia are implicated in the restriction of amyloid deposits and play a major role in internalization and degradation of Aβ. Recent studies showed that rare variants of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) are associated with an increased risk for AD. Post-translational modifications of Aβ could modulate the interaction with TREM2, and the uptake by microglia. Here, we demonstrate that genetic deletion of TREM2 or expression of a disease associated TREM2 variant in mice lead to differential accumulation of modified and non-modified Aβ species in extracellular plaques and intraneuronal deposits. Human brains with rare TREM2 AD risk variants also showed altered deposition of modified Aβ species in the different brain lesions as compared to cases with the common variant of TREM2. These findings indicate that TREM2 plays a critical role in the development and the composition of Aβ deposits, not only in extracellular plaques, but also intraneuronally, that both could contribute to the pathogenesis of AD.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Aβ
|2 Other
650 _ 7 |a Intraneuronal
|2 Other
650 _ 7 |a Microglia
|2 Other
650 _ 7 |a Post-translational modification
|2 Other
650 _ 7 |a TREM2
|2 Other
650 _ 7 |a Vascular deposits
|2 Other
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: chemistry
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Membrane Glycoproteins: genetics
|2 MeSH
650 _ 2 |a Membrane Glycoproteins: metabolism
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Neurons: pathology
|2 MeSH
650 _ 2 |a Plaque, Amyloid: chemistry
|2 MeSH
650 _ 2 |a Plaque, Amyloid: pathology
|2 MeSH
650 _ 2 |a Receptors, Immunologic: genetics
|2 MeSH
650 _ 2 |a Receptors, Immunologic: metabolism
|2 MeSH
700 1 _ |a Riffel, Florian
|0 0000-0001-8594-100X
|b 1
700 1 _ |a Kumar, Sathish
|0 0000-0002-2792-7047
|b 2
700 1 _ |a Villacampa, Nàdia
|0 P:(DE-2719)9000326
|b 3
|u dzne
700 1 _ |a Theil, Sandra
|b 4
700 1 _ |a Parhizkar, Samira
|0 0000-0001-5807-190X
|b 5
700 1 _ |a Haass, Christian
|0 P:(DE-2719)2202037
|b 6
|u dzne
700 1 _ |a Colonna, Marco
|b 7
700 1 _ |a Heneka, Michael
|0 P:(DE-2719)2000008
|b 8
|u dzne
700 1 _ |a Arzberger, Thomas
|0 P:(DE-2719)2811333
|b 9
|u dzne
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 10
|u dzne
700 1 _ |a Walter, Jochen
|0 P:(DE-HGF)0
|b 11
773 _ _ |a 10.1186/s40478-021-01263-x
|g Vol. 9, no. 1, p. 168
|0 PERI:(DE-600)2715589-4
|n 1
|p 168
|t Acta Neuropathologica Communications
|v 9
|y 2021
|x 2051-5960
856 4 _ |u https://pub.dzne.de/record/162686/files/DZNE-2021-01343.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/162686/files/DZNE-2021-01343.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:162686
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9000326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2202037
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000008
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811333
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2810441
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2021
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-01-28
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL COM : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:20:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:20:11Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-02-14T16:20:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-09
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ACTA NEUROPATHOL COM : 2021
|d 2022-11-09
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1011301
|k Biomarker
|l Interventional Trials and Biomarkers in Neurodegenerative Diseases
|x 1
920 1 _ |0 I:(DE-2719)1110001
|k AG Herms
|l Translational Brain Research
|x 2
920 1 _ |0 I:(DE-2719)1140013
|k Neuropathology / Brainbank
|l Neuropathology / Brainbank
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1011301
980 _ _ |a I:(DE-2719)1110001
980 _ _ |a I:(DE-2719)1140013
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21